Fate Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate, Sales $1.907M Beat $1.011M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsNews
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 12.12 percent increase over losses of $(0.33) per share from
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 12.12 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $1.907 million which beat the analyst consensus estimate of $1.011 million by 88.64 percent. This is a 71.84 percent decrease over sales of $6.772 million the same period last year.